AgelessRx

We just made the finals of the biggest longevity competition in the world.

Out of 800+ teams, we're one of 10 chosen to try to answer a wild question: can the right combination of treatments make your muscles, brain, and immune system function 10 to 20 years younger, in under a year?

Here's the part almost no one is testing. We're not chasing one miracle pill. Aging doesn't break down one system at a time, so we're combining several therapies already used in longevity care to find the precise stack that works together.

Because the goal was never a number on a lab report.

It's more time being strong, sharp, and healthy enough to actually live. More travel. More movement. More years with the people who matter.

That's what we're working toward. And now we get to prove it.

What would you do with 10 extra healthy years? Tell us below.

(For educational purposes only)

Chronological age has always been a blunt instrument. It tells you how long you've been alive, but nothing about how well your body is actually aging or what's driving the gap between the two.

Epigenetic clocks are changing that. By measuring chemical changes to DNA that accumulate over time, biological age tests can give a more granular picture of how your cells are aging, independent of the year you were born. Two people born in the same year can be aging at dramatically different biological rates, and these tools are designed to capture exactly that difference.

But the conversation around these clocks is more nuanced than most people realize. In a recent discussion between longevity researcher Matt Kaeberlein and Matt Dawson, CEO of Tru Diagnostic, they raised questions the field is still working through. Do present-day clocks have real clinical utility, or are they measuring something that doesn't yet translate into actionable decisions? Are they reliable as standalone tools, or do they only become meaningful as part of a broader panel of validated assessments? And critically, is biological age a stable number or a highly dynamic process that responds to what you do day to day?

The emerging view is that biological age is far more dynamic than a single snapshot suggests. It responds to sleep, stress, exercise, and targeted interventions, which makes it a powerful tracking tool when used correctly and interpreted carefully.

Knowing your biological age is only the starting point. What matters is what you do with that information.

Take the assessment at the link in bio.

(For educational purposes only)

A study published in JAMA is making the rounds, and a lot of people in the longevity space are calling it the definitive evidence that Metformin doesn't work as a geroprotective drug. The conclusion sounds clean, but the science is more complicated than that.

The study in question is a long-term follow-up of the Diabetes Prevention Program, one of the most well-designed trials in metabolic medicine. Lifestyle intervention delivered a statistically significant reduction in multimorbidity risk versus placebo. Metformin did not. On the surface, that's not a great signal for Metformin's longevity benefits.

But one detail is getting almost no attention in this conversation, and it changes the interpretation significantly. The dose used in the DPP was 850mg twice daily, 1,700mg per day. That is an aggressive clinical dose designed for blood sugar control and weight management in prediabetic patients. It is nearly double the lower, personalized doses that longevity medicine typically works with today, which generally sit at 1,000mg or less.

This matters for several reasons. Higher doses of Metformin are associated with greater GI side effect burden and worse adherence, increased risk of B12 deficiency, and critically, blunted exercise adaptations. At higher doses, What may function as a beneficial mitochondrial stress signal at lower doses could tip into chronic mitochondrial stress that impairs cellular function at higher doses.

There is also growing evidence that Metformin's blood sugar lowering effects and its effects on mitochondrial function, cellular senescence, and inflammation operate on somewhat separate biological axes. The dose optimized for one may not be the dose that unlocks the other.

The JAMA study raises important questions. But the question it raises for us isn't whether Metformin works for longevity. It's whether we've been studying the right dose to find out.

Learn more about Metformin at the link in bio.

(For educational purposes only)

The weight loss story around GLP-1 and GIP medications has always been the headline. The more interesting story is what's happening underneath it.

New research presented at the Endocrine Society's annual meeting found that Tirzepatide doesn't just reduce fat, but it appears to change what fat actually is. Specifically, it seems to convert white fat, a largely passive storage tissue that holds energy but does little else, into brown fat, which is metabolically active, burns sugar, generates heat, and is dense with mitochondria.

That last detail matters more than it might seem. What makes brown fat biologically distinct is its mitochondrial content. The more mitochondria a fat cell contains, the more metabolically active it becomes. As we age, brown fat decreases and white fat increases, a shift that tracks closely with the metabolic decline associated with aging. If Tirzepatide is reversing that shift, it may be doing something researchers didn't fully anticipate: functioning as a mitochondrial-enhancing drug, independent of how much weight is lost.

This raises a question worth taking seriously. If this effect is happening in fat cells, does it extend to other cell types and organ systems? Early data in brain tissue suggests this may be the case. Mitochondrial decline is one of the most consistently documented drivers of biological aging, underlying cellular energy production, immune function, and cognitive health. A drug that supports mitochondrial health independent of weight loss may belong in the longevity conversation, not just the metabolic one.

The research is early and the questions are still open, but the direction is consistent with how we have been thinking about this drug class for some time.

Learn more about Tirzepatide at the link in bio.

(For educational purposes only)

The FDA just spent two days reviewing seven popular peptides, including BPC-157 + TB-500, MOTS-c, and KPV.
So, what exactly does this mean?

This was not an approval process. An advisory committee looked at whether these peptides are safe enough to be used in compounded treatments.

A vote here doesn't mean a peptide is now proven safe, effective, or ready for the market.

But it does raise the right questions. Questions the peptide industry often skips:

➡️What human evidence supports the proposed use?
➡️Does the dose and formulation match what was actually tested?
➡️Can you trace where it came from and what's really in it?

We've been asking these questions for a while. That's why we're building the AgelessRx Peptide Standard, backed by our in-house clinical team (199+ years of combined experience) and our Stanford PhD-led Research Team.

Because "cheaper somewhere else" doesn't mean "as tested" or "as safe."

We'll share the standard soon. Follow along to see how we're defining the bar.

(For educational purposes only)

Muscle loss is one of the most common concerns raised about GLP-1 medications, and it deserves a more precise answer than it usually gets.

A recently published mouse study added ketone supplementation to Semaglutide treatment in an obese mouse model. The finding was notable: muscle loss was reduced by approximately 67% compared to Semaglutide alone, with no meaningful difference in the amount of fat lost. The weight loss benefit remained intact. The muscle loss did not.

But before drawing conclusions from a single mouse study, the more important reframe is worth understanding. Muscle loss during GLP-1 treatment is not a GLP-1 specific problem. It is a calorie deficit problem. Any significant weight loss, regardless of how it is achieved, carries the same risk of lean mass loss. GLP-1 medications are being scrutinized more closely on this point simply because they are more effective at creating that deficit than most other interventions available.

This distinction matters because muscle is not just a cosmetic concern. It functions as a metabolically active endocrine organ, influencing insulin sensitivity, immune function, inflammatory regulation, and through its production of neurotrophic factors, cognitive health. Large observational studies consistently show grip and leg strength as among the most robust predictors of longevity, independent of age, BMI, and activity level. Preserving muscle mass during any weight loss or metabolic intervention is not optional for anyone thinking seriously about healthspan.

The ketone supplementation finding is hypothesis-generating, not conclusive. Human trials are needed. But the direction it points is worth paying attention to as the research matures.

Learn more about GLP-1s the link in bio.

(For educational purposes only)